

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>  
October 22th, 2025

Company:	Chordia Therapeutics, Inc
Representative:	Chief Executive Officer Hiroshi Miyake (Security Code: 190A TSE Growth Market)
Contact:	Chief Financial Officer Masaru Okatani

## **Announcement on the Reduction of Capital Reserve and Appropriation of Surplus**

Kanagawa Japan

October 22th, 2025 – Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; Chief Executive Officer: Hiroshi Miyake) (“Chordia”) announced that pursuant to Article 370 of the Companies Act and the provisions of our Articles of Incorporation, a written resolution in lieu of a resolution of the Board of Directors dated October 22, 2025, has been adopted to reduce the amount of capital reserve and appropriate surplus, as outlined below.

### **1. Purpose of the Reduction of Capital Reserve**

The purpose of this reduction is to offset the current deficit and strengthen our financial foundation, while enhancing flexibility and agility in future capital policies and optimizing our capital structure. In accordance with Article 459, Paragraph 1 of the Companies Act and the provisions of our Articles of Incorporation, the capital reserve will be reduced and transferred to other capital surplus. Subsequently, the increased other capital surplus will be transferred to retained earnings brought forward and applied to offset the deficit in retained earnings brought forward. Please note that this transaction falls under the proviso of Article 449, Paragraph 1 of the Companies Act, and therefore does not require procedures for creditor objections.

### **2. Details of the Reduction of Capital Reserve**

In accordance with Article 448, Paragraph 1 of the Companies Act, the capital reserve will be reduced and the same amount will be transferred to other capital surplus.

- (1) Item and amount to be reduced: Capital reserve — ¥4,634,982,843
- (2) Item and amount to be increased: Other capital surplus — ¥4,634,982,843

### **3. Details of the Appropriation of Surplus**

In accordance with Article 452 of the Companies Act, the other capital surplus transferred in Section 2 above will be further transferred to retained earnings brought forward and applied to offset the deficit.

## Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

[ir@chorditherapeutics.com](mailto:ir@chorditherapeutics.com)



- 
- (1) Item and amount to be reduced: Other capital surplus — ¥7,507,647,156
  - (2) Item and amount to be increased: Retained earnings brought forward — ¥7,507,647,156

#### 4. Schedule

- (1) Date of resolution: October 22, 2025
- (2) Effective date: October 22, 2025

#### 5. Future Outlook

This transaction involves a transfer between items within net assets and does not affect the total amount of net assets or the number of shares issued. Accordingly, there will be no change in net assets per share.

#### **About Chordia Therapeutics**

Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including CTX-177, a MALT1 inhibitor, CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website <https://www.chorditherapeutics.com/en/>.